51 results about "MC3T3" patented technology

The invention provides a bone organ model as well as a construction method and application thereof, and the method comprises the following steps: arranging a biological material with a micropore array in a cell culture plate to obtain a bone organ chip; suspending the initial stem cells in a culture medium, and promoting the cells to form a spherical structure through cell aggregation or by using a non-adhesive culture surface, so as to obtain cell spheres; and culturing the cell spheres in the bone organ chip by adopting the culture medium for constructing the bone organ model to obtain the bone organ model. The skeletal organ is successfully constructed through in-vitro self-organized 3D co-culture initial stem cells including embryonic stem cells, induced pluripotent stem cells, bone marrow mesenchymal stem cells, osteoblasts, bone cells, all levels of osteogenic precursor cells, osteogenic-like cells and MC3T3-E1 cells, and the skeletal organ can become an important tool for researching and treating bone related diseases.

The invention discloses combined lactobacillus salivarius CCFM1398 for regulating and controlling bone homeostasis and relieving bone resorption and a metagen of the combined lactobacillus salivarius CCFM1398, and belongs to the technical field of microorganisms. The combined lactobacillus salivarius CCFM1398 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that expression of protein level and gene level of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors TNF-alpha, IL-6 and MPO of the orthodontic bone absorption rat is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention provides a milk protein peptide which takes milk protein as a raw material and has the effects of promoting calcium absorption and improving bone health and application of the milk protein peptide. Specifically, milk protein peptide sequences, including YGGVSL and SQRY, are screened by adopting enzymolysis, sequence identification and molecular docking methods. The milk protein peptide is proved to have high calcium transport promoting capacity in the in-vitro intervention of Caco-2 cells, and the milk protein peptide is proved to have the capacity of promoting osteogenesis and inhibiting bone resorption in the in-vitro intervention of MC3T3-E1 mouse embryo osteoblasts. In animal experiments, by increasing the content of blood calcium and bone calcium, reducing the content of excrement calcium, improving mRNA expression of calcium ion channel protein, calcium binding protein and peptide transporter in intestinal tracts, enhancing the efficiency of calcium entering blood, promoting osteogenesis and inhibiting bone resorption, the milk protein peptide is comprehensively proved to have the capabilities of improving calcium resorption of organisms and improving bone health. The milk protein peptide has both functionality and nutrition, and has a wide application prospect in the aspect of bone health.

The invention discloses a combined lactobacillus salivarius CCFM1397 for improving osteoblast activity and relieving bone resorption and periodontal tissue damage and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus salivarius combination CCFM1397 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that: the expression of MC3T3-E1 cell osteoprotegerin (OPG) protein and gene level is improved in vitro; the bone absorption amount of orthodontic bone absorption rat alveolar bone is reduced, the number of alveolar bone osteoclasts is reduced, and the level of rat serum OPG is improved; the secretion of inflammatory factors IL-1beta, IL-6 and TNF-alpha and myeloperoxidase MPO of the orthodontic bone absorption rats is reduced; and the pathological condition of orthodontic bone absorption rat alveolar bone tissue is improved. Therefore, the combined lactobacillus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention discloses copper selenide / tricalcium silicate bone cement. The bone cement comprises a liquid phase component and a solid phase component, the liquid phase component is water, and the solid phase component is tricalcium silicate powder and copper selenide nanoparticles. Compared with the existing tricalcium silicate bone cement, the tricalcium silicate bone cement has the advantages that by introducing a trace amount of copper selenide nanoparticles, not only can the hydration and coagulation time of tricalcium silicate be shortened, but also the porosity and degradation rate of the tricalcium silicate after coagulation and solidification can be reduced, the compressive strength can be improved, the stimulation effect on ALP activity of MC3T3-E1 cells can be enhanced, the survival rate of the MC3T3-E1 cells can be improved, and the application prospect is broad. The immunogenic apoptosis of K7M2-wt cells is promoted, and the tumor growth rate is reduced. Besides, the introduction of the copper selenide nanoparticles can also endow the tricalcium silicate bone cement with the performance of temperature rise under near-infrared light, so that in clinical application, the tricalcium silicate bone cement can be further combined with a near-infrared technology to realize ablation of bone tumors, and a new strategy is provided for treatment of the bone tumors.

The invention discloses sturgeon cartilage active peptide capable of promoting growth and improving bone development as well as a preparation method and application of the sturgeon cartilage active peptide, and belongs to the technical field of active peptide. According to the invention, sturgeon cartilage is taken as a raw material, polypeptide with the highest activity of promoting bone growth and development is selected from different enzymolysis combinations through MC3T3-E1 cell tests, and the positive effect of the polypeptide is verified through zebra fish tests; then, two potential sturgeon cartilage active peptide sequences with the function of promoting bone growth and development are screened out through bioinformatics technologies such as mass spectrum identification, molecular docking and the like, and the amino acid sequences of the sturgeon cartilage active peptide fragments are shown as SEQ ID NO.2 and SEQ ID NO.5. The sturgeon cartilage peptide prepared by the method disclosed by the invention has the activity of promoting bone growth and development, can solve the problem of high-value utilization of sturgeons, can also be applied to functional products as a functional factor, and has a good application prospect.

The invention relates to the field of biological medicine, and discloses a pTH long-acting polypeptide compound as well as preparation and application thereof. According to the polypeptide, at least one amino acid residue of the 13th, 26th and 27th amino acid residues of a pTH (1-34) parent peptide sequence is connected with octadecanedioic acid or eicosanoic acid and a derivative modification group of octadecanedioic acid or eicosanoic acid, and the polypeptide is covalently combined with a polypeptide skeleton through an AEA-AEA-gamma-Glu connecting unit. The binding capacity of the polypeptide and serum albumin is remarkably enhanced by utilizing a fatty acid side chain modification means, and meanwhile, the half-life period is prolonged. The pTH long-acting polypeptide compound disclosed by the invention has remarkable osteogenic activity promoting effect, can promote proliferation of MC3T3-E1 cells and generate osteogenic markers and calcium nodules under osteogenic induction conditions, and the binding capacity of the pTH long-acting polypeptide compound and serum albumin is improved by 2-6 times. The invention further provides a solid-phase synthesis method of the polypeptide compound and a pharmaceutical composition containing the polypeptide compound, the polypeptide compound can be used for treating osteoporosis and parathyroid hypofunction, and the compliance problem that an existing medicine needs to be injected every day is effectively solved.

The invention discloses a Lactobacillus paracasei strain capable of relieving bone resorption and having an anti-inflammatory effect and a metagen thereof, and belongs to the technical field of microorganisms. The lactobacillus paracasei CCFM1394 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that the expression of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro, and meanwhile, the expression of an RUNX gene of MC3T3-E1 is promoted; therefore, the lactobacillus paracasei has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention relates to the field of detection of active ingredients of traditional Chinese medicines, in particular to application of dodder amine and / or 19 alpha-madecassic acid. According to the application disclosed by the invention, the osteoporosis resisting effect of the cuscutamine, the 19 alpha-hydroxyasitic acid in a mouse MC3T3-E1 cell and the osteoclast differentiation effect of the cuscutamine, the 19 alpha-hydroxyasitic acid in a mouse macrophage RAW 264.7 cell induced by sRANKL are evaluated by using osteoblast differentiation and mineralization. Experimental results show that in an osteoblast or osteoclast activity evaluation system, the cuscutamine, the 19 alpha-hydroxysidic acid has the anti-osteoporosis activity, and in addition, the cuscutamine, the 19 alpha-hydroxysidic acid has the anti-osteoporosis activity. Semen cuscutae amine and 19 alpha-madecassic acid can be used as anti-osteoporosis quality markers of the eight-component kidney tonifying capsules.

This invention discloses an active peptide from sturgeon cartilage that promotes height growth and improves bone development, along with its preparation method and applications, belonging to the field of active peptide technology. Using sturgeon cartilage as raw material, this invention selects the polypeptide with the highest activity in promoting bone growth and development from different enzymatic hydrolysis combinations through MC3T3-E1 cell experiments, and verifies its positive effect using zebrafish experiments. Subsequently, two potential active peptide sequences from sturgeon cartilage with bone growth and development promotion functions are screened using mass spectrometry to identify their sequences and bioinformatics techniques such as molecular docking. The amino acid sequences of the active peptide segments are shown in SEQ ID NO.2 and SEQ ID NO.5. The sturgeon cartilage peptides prepared by this invention have activity in promoting bone growth and development, which can solve the problem of high-value utilization of sturgeon and can also be used as a functional factor in functional products, showing good application prospects.

The invention discloses an osteoblast proliferation promoting peptide as well as a preparation method and application thereof, and belongs to the technical field of protein peptide preparation. The amino acid sequence of the osteoblast proliferation promoting peptide is shown as any one of SEQ ID NO.1-3. The invention further discloses a preparation method of the osteoblast proliferation promoting peptide. The invention also provides a preparation method of the osteoblast proliferation promoting peptide, which comprises the following steps: extracting collagen by using a protease-assisted acid method, and carrying out enzymolysis by using alkaline protease to obtain the osteoblast proliferation promoting peptide. The osteoblast proliferation promoting peptide provided by the invention can promote proliferation and expression of MC3T3-E1 cell differentiation and mineralization related genes through an MAPK pathway, so that osteoporosis is prevented and bone health is improved. And the method has a good application prospect in the fields of bone cell proliferation promoting related orthopaedic and dental medicines, health care products, functional foods and the like.

The invention belongs to the technical field of medicines, and particularly relates to application of TPHP in bone metabolism. According to the application disclosed by the invention, the TPHP is found to have a remarkable inhibition effect on proliferation and invasion and migration of bone cells, and the TPHP damages proliferation, migration and invasion functions of MC3T3-E1 osteoblasts by inhibiting an MAPK / ERK signal channel and down-regulating related gene expression. The action effect of the TPHP is remarkable, and subsequent scientific research is facilitated. In addition, TPHP is easy to obtain and low in cost, related preparations and biological models are easy to prepare, the process is mature, industrialized production can be achieved, and the market acceptance degree is high.

This invention discloses a collagen calcium chelating peptide and its application in the preparation of calcium supplements and osteoporosis prevention products, belonging to the field of food biotechnology. Osteogenic activity evaluation confirmed that the collagen calcium chelating peptide significantly promoted MC3T3-E1 cell proliferation, increased alkaline phosphatase activity, and enhanced mineralized nodule formation within a concentration range of 1-100 μg / mL, exhibiting a clear concentration-dependent effect. Intestinal calcium absorption promotion experiments showed a significant increase in calcium transport compared to the calcium chloride control group, and fluorescence imaging confirmed its effective enhancement of calcium ion uptake in small intestinal epithelial cells. This invention clarifies for the first time the structural characteristics and dual biological activities of a fish scale-derived calcium chelating peptide, revealing its mechanism of action in regulating osteoblasts through the EGFR signaling pathway. This provides a new pathway for the high-value utilization of aquatic by-products and offers a scientific basis and high-quality candidate raw materials for the development of novel functional calcium supplements.

The invention discloses an experimental method for researching the influence of a pulse electromagnetic field on MC3T3-E1, and relates to the technical field of biomedical engineering. Comprising the following steps: S1, culturing cells; s11, preparation of an MC3T3-E1 cell is carried out; s12, carrying out cell passage; s2, pulse electromagnetic field treatment; s21, setting a conventional culture group and a pulse electromagnetic stimulation group, taking a third generation of MC3T3-E1 cells, rinsing the MC3T3-E1 cells twice with a PBS solution free of calcium and magnesium ions, and counting the MC3T3-E1 cells after the MC3T3-E1 cells are prepared into a cell suspension; respectively inoculating into 25ml cell culture flasks and dividing into three groups: a conventional culture group, a conventional culture and pulse electromagnetic stimulation applying group and a conventional culture and pulse electromagnetic stimulation applying group. The invention provides an important theoretical basis for treating osteoporosis by clinically applying the PEMFs; the potential molecular mechanism of PEMFs is disclosed from the perspective of epigenetics methylation regulation.

The invention discloses a preparation method and application of an oyster-derived antioxidant and osteogenesis-promoting bifunctional polypeptide, relates to the technical field of biology, and solves the problem of serious insufficiency in research and utilization of oyster bioactive peptides at present, and the preparation method comprises the following steps: step 1, manually shelling to obtain fresh oyster meat, washing with deionized water, and drying to obtain fresh oyster meat; the fresh oyster meat and the extracting solution A are mixed to obtain a mixture A, the mass volume ratio of the fresh oyster meat to the extracting solution A is 1: 3, the extracting solution A is a phosphate buffer solution, the concentration of the phosphate buffer solution is 0.01 mol / L, and the pH of the phosphate buffer solution is 7.2. The enzymolysis efficiency and the in-vitro antioxidant activity are improved through ultrasonic-assisted enzyme hydrolysis, H2O2-induced MC3T3-E1 cell oxidative stress and osteoblast dysfunction can be reversed, and the method is applied to related functional foods for resisting oxidation, promoting bone growth and delaying bone loss.

This invention relates to the field of biomedicine, disclosing a long-acting pTH polypeptide compound and its preparation and application. The polypeptide has an octadecanoic acid or eicosanoic acid and its derivatives modified by at least one amino acid residue at the 13th, 26th, and 27th amino acid residues of the pTH (1-34) parent peptide sequence, and is covalently bound to the polypeptide backbone via an AEEA-AEEA-γ-Glu linker. This invention significantly enhances the binding ability of the polypeptide to serum albumin and prolongs its half-life by utilizing fatty acid side chain modification. The long-acting pTH polypeptide compound of this invention exhibits significant osteogenic activity, promoting the proliferation of MC3T3-E1 cells and generating osteogenic markers and calcium nodules under osteogenic induction conditions, with a 2-6 fold increase in binding ability to serum albumin. This invention also provides a solid-phase synthesis method for this polypeptide compound and a pharmaceutical composition containing it, which can be used to treat osteoporosis and hypoparathyroidism, effectively solving the compliance problem of existing drugs requiring daily injections.

The invention discloses a shell-derived biphase calcium phosphate composite bone repair material as well as a preparation method and application thereof, and belongs to the field of biomedical materials. According to the preparation method, the shell-source calcium source and the calcium pyrophosphate are mixed, the biphase calcium phosphate (BCP) containing HAP and beta-TCP in different proportions is prepared through wet ball milling and solid-phase reaction, the reaction conditions are controlled in a simple mode, and the proportion of HAP to beta-TCP in the BCP is controllable. The biphase calcium phosphate prepared by the method is further compounded with sodium alginate, and the biphase calcium phosphate-sodium alginate composite scaffold is prepared by freeze drying and Cacrosslinking. The composite scaffold has a suitable porous structure, can exert in-vitro osteogenic induction activity and an in-vivo bone defect repair function, can significantly induce MC3T3-E1 cell alkaline phosphatase activity and induce calcium deposition, has osteogenic induction activity, can induce bone defect repair at an in-vivo rat skull defect part, and has a good application prospect. Excellent bone tissue engineering application prospects are shown.

The invention discloses a method for judging the effect of improving osteoporosis through intervention of bone collagen peptides from various livestock and poultry sources and application of the method, and belongs to the technical field of nutritional and functional foods.By establishing an oxidative stress injury mouse MC3T3-E1 osteoblast model, bone collagen peptides capable of improving proliferative activity are screened, and the osteoporosis improvement effect of bone collagen peptides from various livestock and poultry sources is achieved. The effects of the compound on cell differentiation activity, mineralization activity, cycle regulation and apoptosis inhibition are detected; the improvement effect is analyzed, and an in-vitro activity comprehensive scoring model is established; synchronously detecting the content of bone conversion factors in the cell culture supernatant; carrying out an in-vivo animal experiment on the screening peptide, and detecting the content of animal serum bone conversion factors and thighbone morphological mechanics indexes; and if the correlation coefficient R2 of the cell supernatant and the change rate of the animal serum bone conversion factor is greater than or equal to 0.85, determining that the model is effective and comprehensively judging the activity difference. According to the method, the biological activity difference is efficiently judged, a screening basis is provided for functional bone-derived food development, and high-value utilization of livestock and poultry bone byproducts is promoted.

The invention discloses a milk protein peptide for promoting bone growth as well as a preparation method and application thereof, and belongs to the technical field of bioactive peptides. The preparation method specifically comprises the following steps: (1) adding milk protein into a sodium hydroxide aqueous solution, and homogenizing through a colloid mill; (2) adjusting the pH value to 7.8, carrying out enzymolysis, carrying out enzyme inactivation, and cooling; (3) ultrafiltration and collection; (4) centrifugally filtering, taking supernate, and concentrating; and (5) carrying out spray drying. The milk protein peptide can significantly promote proliferation and differentiation of osteoblasts MC3T3-E1, up-regulate expression of osteogenesis-related genes ALP, promote mineralization of extracellular matrixes, promote proliferation of chondrocytes C28 / I2, and contribute to thickening of cartilage growth plates so as to promote bone growth. The compound can be used for preparing medicines and foods for promoting bone growth, preventing or assisting in treating osteoporosis and promoting bone health, and has the advantages of simple preparation process, low cost and definite components and activity.

The present invention discloses a research and development method for histone methyltransferase Setdb1 in disuse osteoporosis, specifically including the steps of studying the diagnostic application of Setdb1 in disuse osteoporosis; studying the effect of Setdb1 on osteoblast proliferation function; studying the effect of bone-targeted delivery of si-Setdb1 on mouse bone formation and studying the effect of overexpression of Setdb1 on cell proliferation function in a 2D rotational MC3T3-E1 cell unloading model. This scheme found that the expression of histone methyltransferase Sedtb1 was significantly reduced in the 2D rotational cell unloading model and the mouse hindlimb tail suspension (HLU) unloading model, and explored its effect on osteoblast proliferation function and bone formation, suggesting that it may serve as a potential biomarker for disuse osteoporosis and can be used as a new target to combat disuse osteoporosis, with good prospects for translational medicine.

The invention discloses avicennia marina oligosaccharide as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. An alkaline phosphatase staining test and an alizarin red staining test prove that the avicennia marina oligosaccharide AMO-1 can remarkably improve the activity level of alkaline phosphatase in MC3T3 cells and osteogenic mineralization nodules, and can remarkably up-regulate the expression levels of osteogenic differentiation related proteins RUNX2, OSX, OCN and COL1; animal experiments prove that AMO-1 can obviously relieve bone loss of DEX-induced osteoporosis mice, and can be used for preparing medicines for preventing and treating osteoporosis. The oligosaccharide provided by the invention is high in purity, does not contain impurities such as protein, nucleic acid and the like, is small in toxic and side effects, has a wide application prospect in preparation of low-toxicity and high-efficiency anti-osteoporosis medicines, and is beneficial to further development and utilization of avicennia marina resources.

The application discloses a Streptococcus salivarius CCFM1399 and its postbiotic for relieving bone resorption and periodontal tissue damage, and belongs to the technical field of microorganisms. The Streptococcus salivarius CCFM1399 provided by the application is separated from oral plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and specifically has the following effects: improving the expression of osteoprotegerin (OPG) protein level and gene level of MC3T3-E1 cells in vitro; reducing the alveolar bone resorption amount of orthodontic bone resorption rats, reducing the number of osteoclasts in alveolar bone, and improving the OPG level in serum of rats; reducing the secretion of inflammatory factors IL-6, TNF-alpha and MPO of orthodontic bone resorption rats; and improving the pathological condition of alveolar bone tissue of orthodontic bone resorption rats. Therefore, the Streptococcus salivarius has great application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention belongs to the field of biomedical materials and bioengineering films, and particularly relates to a cross-magnetic dielectric effect material and a preparation method thereof, specifically, magnetic metal particles cobalt (Co) and dielectric ceramic (MgF2) are used as raw materials, and the cross-magnetic dielectric effect material is prepared on the surface of titanium through a multi-source sputtering deposition technology. The magnetic nano-particle multi-phase film with the TMD effect is prepared from the magnetic metal with high saturation magnetization and the dielectric ceramic with high dielectric constant. The titanium sheet with the TMD effect is co-cultured with mouse embryo osteoblast precursor cells (MC3T3-E1) and human gingival fibroblasts (HGF-1) to find that the TMD effect of the titanium sheet has good biological safety, and on the basis, preparation parameters of the multiphase membrane are optimized, so that the polarization of macrophages is regulated and controlled by proper magnetic field force generated by the TMD effect of the titanium sheet, and the macrophages with the TMD effect can be obtained. Therefore, osteogenic differentiation of bone marrow mesenchymal stem cells is promoted, titanium surface osseointegration is improved, and the method is expected to serve as a new direction for preparing a surface coating for promoting implant osseointegration.

The invention discloses a bone homeostasis regulating metagen prepared from streptococcus salivarius CCFM1395 and application of the bone homeostasis regulating metagen, and belongs to the technical field of microorganisms. The streptococcus salivarius CCFM1395 provided by the invention is separated from oral dental plaque of healthy teenagers, has the effects of relieving bone resorption and resisting inflammation, and is specifically reflected in that the expression of MC3T3-E1 cell osteoprotegerin (OPG) is improved in vitro. Therefore, the streptococcus salivarius has a huge application prospect in products for relieving bone resorption and assisting in inhibiting periodontal tissue inflammation.

The invention relates to the field of pharmacy, in particular to application of luteolin in preparation of a medicine for treating periprosthetic osteolysis. Experiments show that luteolin has an obvious inhibition effect on osteolysis induced by titanium particles by enhancing expression of FOXO3A, reducing oxidative stress of MC3T3-E1 cells, recovering osteogenesis functions of BMSCs and relieving osteolysis and bone loss induced by the titanium particles, and the luteolin can be used for preparing a medicine for treating osteolysis induced by the titanium particles. The method can be used as a new means for medicine intervention of osteolysis around the prosthesis after artificial prosthesis replacement.

[Problem] The present invention provides an inhibitor or the like, which contains 3, 5-dihydroxy-4-methoxybenzyl alcohol (3, 5-dihydroxy-4-methyloxbenzene alcohol, DHMBA) as an active ingredient, and which is capable of providing a new strategy for preventing and treating bone formation disorders and mineralization disorders of osteoblasts, which are associated with an inflammatory state in the bone marrow microenvironment. [Solution] The present invention is characterized by having 3, 5-dihydroxy-4-methoxybenzyl alcohol (DHMBA) as an active ingredient and having an effect of promoting mineralization of osteoblast MC3T3-E1 cells.

The invention relates to a Ti6Al4V surface micro-arc zinc oxide modified coating and a detection method and application thereof, and belongs to the technical field of material surface coating preparation. In order to solve the problems that an existing titanium oxide coating is poor in antibacterial performance and cannot be applied to a special oral environment, a zinc modified coating is prepared on the surface of Ti6Al4V through micro-arc oxidation, the zinc content of the zinc modified coating is 0-5.16%, a plurality of holes with the diameter being 1-2 micrometers are evenly distributed in the zinc modified coating, the contact angle of the zinc modified coating is 35-60 degrees, and the surface of the zinc modified coating is coated with the antibacterial coating. An oral microenvironment is simulated through antibacterial experiments and bacterium-cell co-culture, and it is verified that the antibacterial performance of the material is improved through introduction of zinc. In addition, the coating plays a role in promoting adhesion, proliferation and osteogenic differentiation capability of MC3T3-E1 cells in conventional and high-glucose states, and the coating is found to have better antibacterial property and hydrophilicity, and optimizes the osseointegration capability of the implant.

The application discloses a fish scale collagen calcium peptide chelate, a preparation method thereof and application of the fish scale collagen calcium peptide chelate in improving intestinal calcium absorption and bone development. The fish scale collagen calcium peptide chelate is prepared by using tilapia processing by-products as raw materials and adopting a high-pressure homogenization pretreatment-papain directional enzymolysis-peptide calcium coordination chelation integrated process. Single-factor experiments are used to systematically optimize chelation process parameters, a Caco-2 small intestinal epithelial cell monolayer model is used to simulate an intestinal barrier, and the calcium transport activity and biological safety of the fish scale collagen calcium peptide chelate are evaluated. The osteogenic activity of the fish scale collagen calcium peptide chelate is verified from three dimensions of cell proliferation, differentiation and mineralization by using an MC3T3-E1 osteoblast model. Cell experiments prove that the chelate has good biological safety, can significantly promote intestinal calcium transport, and can promote osteoblast proliferation, differentiation and dose-dependent mineralization, and has both calcium absorption promotion and osteogenic activity, thereby providing a new way for high-value utilization of fish scales and research and development of new calcium supplement products.

The application discloses application of water extract of Euryale ferox in preparation of food and medicine for improving osteoporosis, and relates to the technical field of natural medicine. The raw Euryale ferox, salt-fried Euryale ferox and bran-fried Euryale ferox are respectively used as raw materials, and the water extract of Euryale ferox is prepared by using a water extraction process after standard cleaning and processing. A double pharmacodynamic evaluation system of a prednisolone-induced zebra fish skull osteoporosis in vivo model and an MC3T3-E1 cell osteogenic differentiation in vitro model is established, and the in-vivo anti-osteoporosis effect, embryonic development safety, in-vitro cytotoxicity and osteogenic differentiation activity of the water extract of Euryale ferox with different processing methods and different concentrations are systematically investigated. The salt-fried Euryale ferox has better pharmacodynamic effect than the raw Euryale ferox and the bran-fried Euryale ferox under the same concentration. The application provides a scientific basis for the application of Euryale ferox in the development of anti-osteoporosis drugs.

The present invention discloses a chitosan oligosaccharide peptide calcium chelate, its preparation method and application. In the present invention, polypeptides with potential calcium absorption promoting activity in walnut protein peptides are screened by molecular docking and glycosylated modification is carried out to prepare peptide calcium complexes. Based on structural characterization, in vitro stability experiments, Caco-2 cell monolayer model, and MC3T3-E1 cell induced differentiation model, the binding effect, stability and calcium absorption promoting mechanism of glycosylated walnut peptide chelates are explored. The results show that COS-AERGVLYR-Ca has good thermal stability, gastrointestinal stability, anti-phosphate crystallization inhibition ability and better calcium transport ability.